Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.
Aperture Venture Partners is a venture capital group committed to working with exceptional entrepreneurs to tackle significant problems and create major new opportunities. Aperture works exclusively within the dynamic and growing healthcare industry. Its principals have been entrepreneurial leaders in the healthcare and investment industries over the past 30 years. They have successfully invested more than $1 billion and founded companies that have had combined revenues greater than $2 billion.
Borealis sources unique early-stage investment opportunities in the areas of application software, digital media, and life sciences. As founders’ partners and active investors, we leverage our operating expertise and networks to add value, mitigate risk, and accelerate growth. Our investments are concentrated in Northern New England (Boston and north), but we invest nationally within our sectors of expertise.
De Novo Ventures, founded in 2000, is a venture capital firm specializing in life science companies. Located in Menlo Park, California the firm invests nationally with a focus on the Western US. The fund managers combine significant entrepreneurial, operating and investment experience. As entrepreneurs they founded or co-founded 4 companies including CardioThoracic Systems, Gynecare, Integrated Vascular Systems, and Origin Medsystems. The firm has $650 million under management.
Echelon Venture’s mission is to maximize shareholder returns by funding companies, guided by competent management, whose potential breakthrough technology can create multiples of value on relatively small amounts of invested capital. It is Echelon Ventures view that the technological breakthrough to drive such value creation is more likely to occur through the innovative combinations of technologies or disciplines than within a single technology sector. We believe that Echelon Ventures is the first venture firm designed specifically to identify, evaluate, and manage investments in companies of this nature.
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include: Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH), and Morphotek (acquired by Eisai). Additional notable portfolio companies include: Affinnova, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics.
For more than 35 years, InterWest has partnered with exceptional entrepreneurs to build winning technology and healthcare companies. With more than 200 years of combined operating and investing experience, the firm’s investing team has raised $2.8B, completed 85 IPOs, and participated in over 80 upside acquisitions. As the firm invests InterWest X, a $650M fund, the InterWest team continues to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $15 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 100 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.
Prism VentureWorks is an early stage venture capital firm focused on disruptive segments in the Digital Media, Life Sciences, and Software & Services sectors. The firm is comprised of a committed team of investors whose industry operating heritage and domain depth make them valued partners among entrepreneurs and syndicates in building successful businesses. Founded in 1996, the Firm has approximately $1.25 billion in capital under management and is based in Needham, MA.
SCP Vitalife is a venture capital fund focused on life science investments in Israel and the U.S. The fund invests in early to mid-stage companies with break-through products that meet a current medical need and are protected by strong intellectual property. The SCP Vitalife team includes investment professionals with prior experiences as senior executives, clinical practitioners and venture capitalists. With offices in Tel Aviv, Israel, and suburban Philadelphia, SCP Vitalife provides hands-on strategic assistance to portfolio companies, often augmenting and enhancing their business development efforts.
Third Point LLC is an SEC-registered investment adviser headquartered in New York, managing approximately $14.5 billion in assets. Founded in 1995, Third Point follows an event-driven approach to global investing.